Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction

BACKGROUND: Sorafenib is the only FDA-approved systemic therapy for advanced hepatocellular carcinoma (HCC). In clinical practice, dose reductions are often required, although there are limited efficacy data related to dose modifications. Given the prevalence of HCC in South Texas, we assessed the e...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Gastrointest Oncol
Main Authors: Al-Rajabi, Raed, Patel, Sukeshi, Ketchum, Norma S., Jaime, Nicole A., Lu, Ting-Wei, Pollock, Brad H., Mahalingam, Devalingam
Format: Artigo
Jezik:Inglês
Izdano: AME Publishing Company 2015
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4397242/
https://ncbi.nlm.nih.gov/pubmed/26029452
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2078-6891.2015.005
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki